Table 2.
Mean survival for breast cancer subclasses stratified for BCL3 high and low in cytosol and nucleus. Survival data were analyzed by the Kaplan–Meier method and log rank p is given. n.a. *Mean survival was not available when all cases were censored. §Analysis restricted to ER-positive cases
| Cytoplasmic BCL3 | Nuclear BCL3 | |||||||
|---|---|---|---|---|---|---|---|---|
| > 8 | Mean survival | SEM | p | > 8 | Mean survival | SEM | p | |
| All cases | Low | 118.6 | 6.0 | 0.046 | Low | 121.6 | 5.8 | 0.002 |
| High | 70.7 | 7.7 | High | 59.0 | 7.2 | |||
| Premenopausal | Low | 112.6 | 12.7 | 0.533 | Low | 115.5 | 11.8 | 0.196 |
| High | 68.8 | 15.1 | High | 50.6 | 12.5 | |||
| Postmenopausal | Low | 118.8 | 6.8 | 0.057 | Low | 122.0 | 6.5 | 0.006 |
| High | 70.0 | 8.6 | High | 58.6 | 8.0 | |||
| Ductal | Low | n.a. * | 0.353 | Low | n.a. * | 0.041 | ||
| High | n.a. * | High | n.a. * | |||||
| Lobular | Low | n.a. * | 0.001 | Low | n.a. * | 0.003 | ||
| High | n.a. * | High | n.a. * | |||||
| Other | Low | n.a. * | 0.564 | Low | n.a. * | 0.317 | ||
| High | n.a. * | High | n.a. * | |||||
| T < 2 | Low | 128.6 | 7.4 | 0.677 | Low | 132.8 | 7.1 | 0.087 |
| High | 82.8 | 10.2 | High | 72.0 | 10.8 | |||
| T > 2 | Low | 91.8 | 7.6 | 0.112 | Low | 94.2 | 7.1 | 0.025 |
| High | 62.4 | 9.4 | High | 44.2 | 6.2 | |||
| N0 | Low | 128.1 | 7.2 | .207 | Low | 133.3 | 6.6 | 0.006 |
| High | 77.9 | 9.6 | High | 54.4 | 6.1 | |||
| N1 | Low | 92.0 | 7.8 | 0.146 | Low | 93.7 | 7.6 | 0.046 |
| High | 47.3 | 9.0 | High | 49.5 | 12.3 | |||
| G1 | Low | 113.5 | 7.2 | 0.536 | Low | n.a. * | 0.552 | |
| High | 57.3 | 5.0 | High | n.a. * | ||||
| G2 | Low | 121.7 | 7.4 | 0.009 | Low | n.a. * | < 0.001 | |
| High | 55.6 | 10.6 | High | n.a. * | ||||
| G3 | Low | 82.9 | 10.3 | 0.975 | Low | n.a. * | 0.665 | |
| High | 73.4 | 11.6 | High | n.a. * | ||||
| ER-neg | Low | 78.8 | 12.7 | 0.454 | Low | 90.8 | 11.3 | 0.376 |
| High | 84.8 | 13.0 | High | 42.4 | 7.6 | |||
| ER-pos | Low | 123.8 | 6.3 | 0.005 | Low | 123.8 | 6.3 | 0.004 |
| High | 60.5 | 8.4 | High | 60.4 | 8.2 | |||
| PR-neg | Low | 93.5 | 8.2 | 0.740 | Low | 98.4 | 7.6 | 0.108 |
| High | 75.7 | 10.3 | High | 55.8 | 10.3 | |||
| PR-pos | Low | 124.6 | 7.4 | 0.017 | Low | 125.2 | 7.3 | 0.007 |
| High | 64.5 | 9.6 | High | 50.1 | 7.4 | |||
| HER2-neg | Low | 125.3 | 6.4 | 0.019 | Low | 126.8 | 6.1 | 0.002 |
| High | 72.1 | 8.9 | High | 61.8 | 8.6 | |||
| HER2-pos | Low | 74.9 | 10.3 | 0.683 | Low | 82.6 | 10.2 | 0.361 |
| High | 57.0 | 9.0 | High | 45.0 | 7.8 | |||
| No TNBC | Low | n.a. * | 0.024 | Low | 123.8 | 6.0 | 0.003 | |
| High | n.a. * | High | 61.0 | 7.7 | ||||
| TNBC | Low | n.a. * | 0.357 | Low | 92.6 | 14.3 | 0.280 | |
| High | n.a. * | High | 43.3 | 14.5 | ||||
| Radiotherapy no | Low | 108.7 | 7.5 | 0.107 | Low | 108.6 | 7.6 | 0.133 |
| High | 67.5 | 12.3 | High | 56.0 | 8.7 | |||
| Radiotherapy yes | Low | 114.2 | 7.7 | 0.180 | Low | 118.6 | 7.2 | 0.008 |
| High | 69.1 | 9.4 | High | 55.8 | 8.7 | |||
| Ki-67 < 2 | Low | 129.9 | 6.3 | 0.012 | Low | 133.5 | 5.9 | < 0.001 |
| High | 59.6 | 10.6 | High | 49.5 | 6.9 | |||
| Ki-67 ≥ 2 | Low | 70.2 | 10.6 | 0.747 | Low | 75.5 | 9.8 | 0.919 |
| High | 70.6 | 11.0 | High | 59.8 | 11.1 | |||
| Chemotherapy no | Low | 133.1 | 6.1 | 0.019 | Low | 131.5 | 6.2 | 0.03 |
| High | 72.9 | 9.3 | High | 58.0 | 7.6 | |||
| Chemotherapy yes | Low | 101.7 | 8.9 | 0.379 | Low | 107.6 | 8.7 | 0.028 |
| High | 64.4 | 10.7 | High | 48.9 | 8.6 | |||
| No endocrine therapy | Low | n.a. * | 0.171 | Low | 85.3 | 12.5 | 0.861 | |
| High | n.a. * | High | 48.1 | 11.1 | ||||
| Tamoxifen | Low |
n.a. * n.a. *§ |
< 0.001 < 0.001§ |
Low |
121.4 124.7§ |
7.7 7.6§ |
< 0.001 < 0.001§ |
|
| High |
n.a. * n.a. *§ |
High |
36.7 36.2§ |
6.3 | ||||
| Aromatase Inhibitor | Low |
n.a. * n.a. *§ |
0.108 0.122§ |
Low |
111.0 108.8 |
8.1 9.0 |
0.53 0.463§ |
|
| High |
n.a. * n.a. *§ |
High |
95.7 95.7 |
6.0 6.0 |
||||